Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now official registry

Gender Dysphoria clinical trials

Every US clinical trial registered for Gender Dysphoria — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.

9 US clinical trials · 5 currently recruiting

The research picture

Gender Dysphoria has 9 registered US clinical trials, 5 of them open to new participants right now — about 56% of the total.

5
recruiting participants now
56%
of trials open to enrollment
3
in Phase 3–4 (later-stage)
2
top sponsor: University of Pittsburgh

Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.

Active & Recent Trials

RECRUITING Phase 3 640 participants

Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries

Cedars-Sinai Medical Center

NCT04979338

RECRUITING Phase 4 256 participants

Effect of Nitropaste in Chest Masculinizing Surgery

University of Virginia

NCT06428669

RECRUITING 90 participants

Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth

University of Colorado, Denver

NCT04596592

RECRUITING NA 78 participants

Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy

University of California, San Francis

NCT07147166

RECRUITING Phase 3 48 participants

Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy

Women and Infants Hospital of Rhode Island

NCT06969326

ACTIVE NOT RECRUITING 150 participants

Testicular Tissue Cryopreservation in the Setting of Gender-Affirming Therapy

University of Pittsburgh

NCT05829928

ACTIVE NOT RECRUITING 20 participants

Ovarian Tissue Cryopreservation in the Setting of Gender-affirming Therapy

University of Pittsburgh

NCT05863676

COMPLETED NA 138 participants

Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria

University of Wisconsin, Madison

NCT05884307

COMPLETED Phase 1 8 participants

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Thomas Jefferson University

NCT04283656

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 2
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Gender Dysphoria Trial Landscape

ClinicalTrials.gov lists 9 US studies indexed under Gender Dysphoria, and 5 of those are currently open to recruitment — roughly 56% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Gender Dysphoria shows 3 late-stage studies (Phase 3 and Phase 4 combined) alongside 1 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Gender Dysphoria is led by University of Pittsburgh with 2 indexed trials, alongside 7 other organizations in the top contributor list. The list on this page surfaces up to 9 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Gender Dysphoria?

PlainTrial tracks 9 US clinical trials for Gender Dysphoria, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Gender Dysphoria?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →